Goodbye Remicade

http://www.marketwatch.com/story/johnson-johnson-announces-patent-and-trademark-office-action-related-to-remicade-2015-02-12

 

There will not be enough contract reps on board to save everyone. Current estimates will have 80-90 contract reps on board by the end of the year through natural attrition, but this will not be enough. Any good contract rep knows they should always be interviewing to find a more permanent job, so we will be stuck with the contract reps not good enough to get a job somewhere else until the downsizing occurs. There has been too much silence since this ruling was announced.

 

JnJ is the big loser in today's stocks. Driven by Biosims and an inability buy cheap opportunity companies. Pharmacyclics being just the latest one to get away. In fact at one point JnJ was the only suitor for Pharmacyclics but failed managed the acquisition and lost out to Abbvie. Just when you think it couldn't get worse.